Clinical Trial

Surgery for Relapsed Ovarian Cancer in Precision

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This multicenter, biomarker-driven, patient-centric study aimed to evaluate the efficacy of secondary cytoreduction followed by platinum-based chemotherapy in combination with anti-PD1/CTLA-4 bispecifics therapy in patients with platinum-sensitive relapsed ovarian cancer (PSROC).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-09-15; most recent amendment 2025-06-24.
Trial Details
NCT Number NCT06602063
Lead Sponsor Shanghai Gynecologic Oncology Group
Collaborators: Shanghai Zhongshan Hospital, Tongji Hospital
Conditions Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Enrollment 33 participants
Start Date 2025-07
Primary Completion 2030-06 (estimated)
Study Completion 2030-06 (estimated)
Updated on ClinicalTrials.gov 2025-06-27